Stockreport

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expec [Read more]